SESSION I

APL BIOLOGY

Genotypic and phenotypic features of APL-like AML
F. Buccisano
SESSION II

UPDATES ON FRONT-LINE TREATMENT

High-risk APL
P. Montesinos
Is disease monitoring still necessary?
R. Dillon
SESSION III

TREATMENT COMPLICATIONS

Differentiation syndrome and others
L. Guarnera
Opening Ceremony and Authorities Greetings

APL past and future
M. Vignetti
SESSION VI

UPDATE IN FRONT-LINE TRIALS AND NEW DRUGS

Chemo-free post-induction therapy for all APL patients
J. Li
UK protocols
N. Russell
SESSION VII

SPECIAL SITUATIONS

APL in children: ATRA + chemotherapy: results of clinical studies in childhood APL
A.M. Testi
APL in the elderly
F. Ferrara
APL in developing countries
E. Rego
SESSION VIII

TREATMENT APPROACHES AT RELAPSE

Conventional and new drugs
M. Breccia
Role of autologous and allogeneic transplantation
A. Rambaldi
EHA AML SWG meeting

Clonal hematopoiesis and prediction to AML
J. Jansen
Classification and risk assessment of AML at diagnosis
K. Döhner
Treatment options for unift elderly AML patients with focus on triplet therapies
S. De Botton
Privacy Policy | Cookie Policy